Integral Molecular, a leader in antibody discovery and characterization, has published new research in the journal mAbs, revealing that as many as one-third of antibody-based drugs exhibit nonspecific binding to unintended targets. A serious concern, off-target drug binding is a significant cause of adverse events in patients, with the potential to even cause death. Analysis of antibody off-target binding across different phases of clinical development suggests this to be a major cause of drug attrition. Early specificity testing could improve drug approvals and patient safety.
In this study, Norden et al. present the first empirical assessment of antibody specificity, quantifying the prevalence of off-target binding across the drug pipeline. They accomplished this through retrospective specificity analyses of leading antibody candidates from biopharmaceutical companies and a prospective study of clinically administered antibody drugs (including those that are given to patients in advanced clinical trials, FDA-approved, or withdrawn). The molecules were tested using the Membrane Proteome Array™ (MPA), a cell-based protein array representing the human membrane proteome, that was developed to test specificity and improve drug safety.
Key Findings (Norden et al., mAbs)
18% of the 83 clinically administered antibody drugs tested showed off-target interactions.
22% of the antibody drugs withdrawn from the market, often due to safety issues, showed nonspecific binding.
33% of the 254 lead molecules tested showed nonspecific binding, a predictor of failure in future stages of development.
